Compare Aspen Aerogels Inc (ASPN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aspen Aerogels Inc vs Incyte Corporation — how do they compare? Aspen Aerogels Inc trades at $6.15 (market cap $509.55M), while Incyte Corporation trades at $120.63 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 48.2× Aspen Aerogels Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.
| ASPN | INCY | |
|---|---|---|
Market Cap | $509.55M | $24.54B |
Sector | Technology | Health |
52-Week High | $8.82 | $129.93 |
52-Week Low | $2.57 | $81.61 |
Enterprise Value | $482.96M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $6.14, down 2.38% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $389.55 million in 2025, though Q2 2026 revenue beat estimates and Q3 guidance suggests recovery. Analyst consensus is strongly bullish with 82.61% buy ratings.
Outlook hinges on execution of revenue growth and margin improvement, particularly in thermal barrier segments. Risks include persistent negative profitability, high cash burn, and competitive pressures in EV materials. The stock offers speculative upside if operational targets are met.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
